Keytruda did not significantly impact long-term health-related quality of life in stage 3 melanoma patients compared to placebo. Both Keytruda and placebo groups returned to baseline quality of life ...
Merck announced that two phase 3 studies of its PD-1 inhibitor Keytruda have failed. (iStock / Getty Images Plus) A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung ...
Maintenance pembrolizumab plus olaparib yielded an ORR of 28% versus 18% with olaparib alone, indicating incremental antitumor activity in a biomarker-defined metastatic pancreatic cancer subgroup.
KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results